• news.cision.com/
  • BICO Group/
  • CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from USPTO

CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from USPTO

Report this content

CELLINK has been granted a patent for a unique cellulose-based bioink technology enabling bioprinting of multiple cell types for cell culturing, tissue engineering and regenerative medicine applications. The patent protection applies to the U.S. market. The company also conducts the process of expanding patent protection in additional countries.

The patent protection (US Patent No. 10,675,379) from the United States Patent and Trademark Office shows uniqueness and height of innovation. This technology is used in CELLINK’s first bioink, CELLINK® bioink, which has expanded into the CELLINK Universal Bioink Series (CELLINK® RGD, CELLINK® Fibrin, CELLINK® Skin, CELLINK® Bone and CELLINK® Laminink), designed to optimize bioprinting of human tissues.

For research involving bioprinting cells such as fibroblasts, stem cells, retinal cells, chondrocytes, osteoblasts, lung cancer cells and liver cancer cells, the easy to use and biocompatible CELLINK bioink promises reliable and precise control during the bioprinting process. Which is good news for scientists bioprinting skin, multicellular, cartilage, bone and cancer tissue models for drug screening applications and regenerative medicine research.

We are immensely excited to have this granted patent for our revolutionary bioink technology and first universal bioink platform. Our user’s needs are unique, and so are our bioinks to address the ever-growing demand for bioink technologies that can provide a biomimetic environment and better control the bioprinting process for creating accurate and predictive tissue models. Our team at CELLINK is excited and thrilled to see the great innovations that continue to flourish from hundreds of labs around the world using the CELLINK bioink series. – Dr. Héctor Martínez, CTO

The granted patent strengthens the company's protection for intellectual properties and complements a full portfolio of bioprinting solutions being developed at CELLINK. 

For further information, please contact:

Erik Gatenholm, CEO                              Gusten Danielsson, CFO

Phone (Sweden): +46 73 267 00 00       Phone (Sweden): +46 70 991 86 04

Phone (US): +1 (650) 515 5566               Phone (US): +1 (857) 332 2138

Email: eg@cellink.com                             Email: gd@cellink.com      

This is information that CELLINK AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through the agency of the contact persons set out above, on June 9, 2020, at 15:05 CEST.


CELLINK is a niche life-science company developing and delivering life-science solutions for cell culturing. We focus on three application areas including bioprinting, analysis and liquid handling & bioprocessing to be able to deliver a complete solution in our life science niche. We target to develop and commercialize cell culture technologies, enabling researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 with installations in more than 55 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq Stockholm Main Market under CLNK B.

Documents & Links